Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Inclusion Criteria: * 18 years of age or older * Male or female * Measurable or evaluable solid tumor malignancy * Relapsed, refractory, locally advanced, or metastatic disease * Disease refractory to or not amenable to standard therapy * Karnofsky performance status 70-100% * Life expectancy 3 months or greater Exclusion Criteria: * Pregnant or lactating women * Primary central nervous system(CNS) malignancy or active CNS metastases * Hematologic malignancy * Chemotherapy within 4 weeks prior to study * Mitomycin C, nitrosoureas within 6 weeks prior to study * High dose chemotherapy with stem cell support within 6 months prior to study * Signal transduction inhibitors, monoclonal antibodies, etc. within 4 weeks prior to study * Systemic hormonal therapy within 4 weeks prior to study * Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study * Radiotherapy within 4 weeks prior to study * Significant cardiovascular disease * Serious/active infection * Major surgical procedures within 2 weeks